« Back
Home /
SB1317 hydrochloride (1204918-72-8(free base))

SB1317 hydrochloride (1204918-72-8(free base))

Item no.	TMO-T4227-10mM
Manufacturer	TargetMol
CASRN	T4227
Amount	10 mM x 1 mL (in DMSO)
Quantity options	100 mg 10 mM x 1 mL (in DMSO) 10 mg 1 mg 1 mL 25 mg 2 mg 50 mg 5 mg
Category	Oncology Reagents & Chemicals Molecules By Organ Colorectal Cancer
Type	Molecules
Specific against	other
Citations	1. William AD, et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kina
Smiles	Cl.CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	TG-02 hydrochloride
Shipping condition	Cool pack
Available
Manufacturer - Targets	JAK\|\|\|FLT\|\|\|CDK
Shipping Temperature	cool pack
Storage Conditions	-20°
Molecular Weight	408, 92
Description	SB1317 hydrochloride (1204918-72-8(free base)) (TG-02 hydrochloride) is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM).
Bioactivity	SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 for the treatment of cancer, with IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively.
Pathways	Stem Cells\|\|\|Cell Cycle/Checkpoint\|\|\|JAK/STAT signaling\|\|\|Chromatin/Epigenetic\|\|\|Tyrosine Kinase/Adaptors\|\|\|Angiogenesis
Receptor	CDK2; FLT3; JAK2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T4227-10mM-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 10 mM x 1 mL (in DMSO)

available

Request delivery time